Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

January 1, 2027

Conditions
Right Heart FailureRight Ventricular Dysfunction
Interventions
DRUG

Combined Epoprostenol Sodium & Milrinone

"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."

DRUG

Normal saline

"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."

All Listed Sponsors
lead

Montreal Heart Institute

OTHER